TME Pharma N.V.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma�s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.�
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 08:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 255.7 KB | |
| 2025-06-18 08:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 386.1 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 388.7 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 261.4 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 222.6 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 329.1 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 286.1 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Inside Information / Other news releases
|
English | 243.3 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Informations privilégiées / Autres communiqués
|
French | 255.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 281.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-04-25 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 351.1 KB | |
| 2025-04-25 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 275.9 KB | |
| 2025-04-10 19:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 224.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Adocia | France | ADOC | |
|
Advicenne | France | ALDVI | |
|
Aelis Farma | France | AELIS | |
|
Aker BioMarine | Norway | AKBM | |
|
ALK-Abelló | Denmark | ALK | |
|
Alligator Bioscience | Sweden | ATORX | |
|
Alvotech Holdings S.A | Luxembourg | ALVO | |
|
AlzeCure Pharma | Sweden | ALZCUR | |
|
Alzinova AB | Sweden | ALZ | |
| ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş. | Türkiye | ANGEN |